Leap Therapeutic SEC Filings

Cypherpunk Technologies Inc. director Richard Christian M acquired common shares through the settlement of previously granted restricted stock units. On March 13, 2026, 74,700 RSUs granted on November 11, 2025 and 94,050 RSUs granted on December 23, 2025 were each settled 1-for-1 into common stock for no cash consideration. Following these compensation-related conversions, he directly holds 168,750 shares of common stock, with no remaining RSUs reported in this filing and no open-market purchases or sales disclosed.

Cypherpunk Technologies Inc. director Mashiach Nissim settled previously granted stock awards into common shares. On March 13, 2026, Nissim exercised and settled 74,700 restricted stock units granted in November 2025 and 94,050 restricted stock units granted in December 2025 on a 1-for-1 basis into the same number of shares of common stock, for no cash consideration. These RSU grants had vested at issuance, and following the settlements Nissim directly owns 168,750 shares of Cypherpunk Technologies common stock. The filing shows no share sales or tax-withholding dispositions associated with these transactions, indicating a net increase in his equity stake.

Cypherpunk Technologies Inc. director Mashiach Nissim settled previously granted stock awards into common shares. On March 13, 2026, Nissim exercised and settled 74,700 restricted stock units granted in November 2025 and 94,050 restricted stock units granted in December 2025 on a 1-for-1 basis into the same number of shares of common stock, for no cash consideration. These RSU grants had vested at issuance, and following the settlements Nissim directly owns 168,750 shares of Cypherpunk Technologies common stock. The filing shows no share sales or tax-withholding dispositions associated with these transactions, indicating a net increase in his equity stake.

Cypherpunk Technologies Inc. director Patricia A. Martin reported the settlement of previously granted restricted stock units into common shares. On March 13, 2026, 74,700 RSUs granted on November 11, 2025 and 94,050 RSUs granted on December 23, 2025 were exchanged on a 1-for-1 basis for common stock at no cash cost.

These RSUs were granted under the company’s 2022 and 2025 equity incentive plans and vested at issuance on their respective grant dates. Following these settlements and related derivative exercises, Martin directly holds 168,750 shares of Cypherpunk common stock, with no remaining RSUs shown in this filing.

Cypherpunk Technologies Inc. director Patricia A. Martin reported the settlement of previously granted restricted stock units into common shares. On March 13, 2026, 74,700 RSUs granted on November 11, 2025 and 94,050 RSUs granted on December 23, 2025 were exchanged on a 1-for-1 basis for common stock at no cash cost.

These RSUs were granted under the company’s 2022 and 2025 equity incentive plans and vested at issuance on their respective grant dates. Following these settlements and related derivative exercises, Martin directly holds 168,750 shares of Cypherpunk common stock, with no remaining RSUs shown in this filing.

Schilsky Richard reported acquisition or exercise transactions in this Form 4 filing.

Cypherpunk Technologies director Richard Schilsky increased his equity stake through RSU settlements, not open-market buying. On March 13, 2026, 74,700 Restricted Stock Units granted on November 11, 2025 and 94,050 RSUs granted on December 23, 2025 were each settled 1-for-1 into common shares for no cash consideration. Both RSU awards had vested at issuance. Following these conversions, Schilsky directly holds 168,750 shares of Cypherpunk Technologies common stock as reported in the filing.

Schilsky Richard reported acquisition or exercise transactions in this Form 4 filing.

Cypherpunk Technologies director Richard Schilsky increased his equity stake through RSU settlements, not open-market buying. On March 13, 2026, 74,700 Restricted Stock Units granted on November 11, 2025 and 94,050 RSUs granted on December 23, 2025 were each settled 1-for-1 into common shares for no cash consideration. Both RSU awards had vested at issuance. Following these conversions, Schilsky directly holds 168,750 shares of Cypherpunk Technologies common stock as reported in the filing.

Cypherpunk Technologies director Joseph Loscalzo acquired 168,750 common shares through RSU settlements. On March 13, 2026, 74,700 RSUs granted on November 11, 2025 and 94,050 RSUs granted on December 23, 2025 were each settled on a 1-for-1 basis for common stock at no cash exercise price.

Both RSU grants had vested at issuance under the company’s 2022 and 2025 Equity Incentive Plans, and this Form 4 shows a compensation-related derivative exercise rather than any open-market buying or selling. Following these transactions, Loscalzo directly holds 168,750 shares of Cypherpunk common stock with no remaining RSU position reported.

Cypherpunk Technologies director Joseph Loscalzo acquired 168,750 common shares through RSU settlements. On March 13, 2026, 74,700 RSUs granted on November 11, 2025 and 94,050 RSUs granted on December 23, 2025 were each settled on a 1-for-1 basis for common stock at no cash exercise price.

Both RSU grants had vested at issuance under the company’s 2022 and 2025 Equity Incentive Plans, and this Form 4 shows a compensation-related derivative exercise rather than any open-market buying or selling. Following these transactions, Loscalzo directly holds 168,750 shares of Cypherpunk common stock with no remaining RSU position reported.

Cypherpunk Technologies Inc. director James H. Cavanaugh acquired shares through the settlement of previously granted restricted stock units (RSUs). On March 13, 2026, 74,700 November 2025 RSUs and 94,050 December 2025 RSUs each settled on a 1-for-1 basis into common stock, totaling 168,750 shares.

These RSUs were granted for no cash consideration under the company’s 2022 and 2025 equity incentive plans and had vested at issuance. After these non‑cash, compensation-related exercises/conversions, Cavanaugh directly owned 168,963 shares of Cypherpunk common stock, with no open‑market buying or selling reported in this filing.

Cypherpunk Technologies Inc. director James H. Cavanaugh acquired shares through the settlement of previously granted restricted stock units (RSUs). On March 13, 2026, 74,700 November 2025 RSUs and 94,050 December 2025 RSUs each settled on a 1-for-1 basis into common stock, totaling 168,750 shares.

These RSUs were granted for no cash consideration under the company’s 2022 and 2025 equity incentive plans and had vested at issuance. After these non‑cash, compensation-related exercises/conversions, Cavanaugh directly owned 168,963 shares of Cypherpunk common stock, with no open‑market buying or selling reported in this filing.

Cypherpunk Technologies Inc. reports a transformed business model that combines a privacy-focused digital asset strategy with ongoing cancer drug development. The company changed its name from Leap Therapeutics to reflect a new emphasis on Zcash, a privacy-preserving blockchain network and digital asset.

Cypherpunk is accumulating ZEC as a digital asset treasury; as of March 11, 2026 it held 294,743.10 ZEC at an average purchase price of $335.89, about 1.76% of circulating supply, with a goal of reaching at least 5% over time. The firm also invested $5 million in Zcash Open Development Lab to support the core Zcash wallet and protocol development.

Through its Leap Therapeutics subsidiary, the company continues to develop sirexatamab (DKN-01) for colorectal cancer and other indications, with Phase 2 data showing higher response rates and longer progression-free survival in biomarker-selected patients. A second program, FL-501, targets GDF-15 for cachexia and related conditions. Extensive patent portfolios and licensing agreements with Eli Lilly and Adimab underpin its biotechnology assets.

Cypherpunk Technologies Inc. reports a transformed business model that combines a privacy-focused digital asset strategy with ongoing cancer drug development. The company changed its name from Leap Therapeutics to reflect a new emphasis on Zcash, a privacy-preserving blockchain network and digital asset.

Cypherpunk is accumulating ZEC as a digital asset treasury; as of March 11, 2026 it held 294,743.10 ZEC at an average purchase price of $335.89, about 1.76% of circulating supply, with a goal of reaching at least 5% over time. The firm also invested $5 million in Zcash Open Development Lab to support the core Zcash wallet and protocol development.

Through its Leap Therapeutics subsidiary, the company continues to develop sirexatamab (DKN-01) for colorectal cancer and other indications, with Phase 2 data showing higher response rates and longer progression-free survival in biomarker-selected patients. A second program, FL-501, targets GDF-15 for cachexia and related conditions. Extensive patent portfolios and licensing agreements with Eli Lilly and Adimab underpin its biotechnology assets.

Cypherpunk Technologies reported a sharp turnaround for 2025, posting net income of $4.8 million after a net loss of $67.8 million in 2024. Results were driven mainly by a $50.4 million unrealized gain on the fair value of its Zcash (ZEC) digital asset treasury.

Operating expenses fell as research and development dropped to $25.7 million and general and administrative to $10.9 million, helped by reduced clinical and payroll costs following completion of the sirexatamab Phase 2 program and headcount reductions. At year-end 2025, cash and cash equivalents were $14.0 million, while ZEC treasury holdings recorded as a digital asset receivable totaled $147.4 million, reflecting the company’s new privacy-technology and Zcash-focused strategy funded by a prior $58.88 million private placement.

Cypherpunk Technologies reported a sharp turnaround for 2025, posting net income of $4.8 million after a net loss of $67.8 million in 2024. Results were driven mainly by a $50.4 million unrealized gain on the fair value of its Zcash (ZEC) digital asset treasury.

Operating expenses fell as research and development dropped to $25.7 million and general and administrative to $10.9 million, helped by reduced clinical and payroll costs following completion of the sirexatamab Phase 2 program and headcount reductions. At year-end 2025, cash and cash equivalents were $14.0 million, while ZEC treasury holdings recorded as a digital asset receivable totaled $147.4 million, reflecting the company’s new privacy-technology and Zcash-focused strategy funded by a prior $58.88 million private placement.

Cypherpunk Technologies Inc. received a notice from Nasdaq that its common stock has closed below the required $1.00 per share minimum bid price for 30 consecutive business days, putting it out of compliance with Nasdaq Listing Rule 5550(a)(2).

The notice is a deficiency warning, not an immediate delisting, and the stock continues to trade on the Nasdaq Capital Market. The company has 180 days, until August 31, 2026, to regain compliance by maintaining a closing bid of at least $1.00 for 10 straight business days, and may qualify for an additional 180-day period if other listing standards are met.

Cypherpunk plans to monitor its share price and may pursue options such as a reverse stock split to restore compliance, but there is no assurance it will succeed within the initial or any additional compliance period.

Cypherpunk Technologies Inc. received a notice from Nasdaq that its common stock has closed below the required $1.00 per share minimum bid price for 30 consecutive business days, putting it out of compliance with Nasdaq Listing Rule 5550(a)(2).

The notice is a deficiency warning, not an immediate delisting, and the stock continues to trade on the Nasdaq Capital Market. The company has 180 days, until August 31, 2026, to regain compliance by maintaining a closing bid of at least $1.00 for 10 straight business days, and may qualify for an additional 180-day period if other listing standards are met.

Cypherpunk plans to monitor its share price and may pursue options such as a reverse stock split to restore compliance, but there is no assurance it will succeed within the initial or any additional compliance period.

Cypherpunk Technologies Inc. (CYPH) is the subject of an amended Schedule 13G filing by Gilead Sciences, Inc. covering its holdings of Cypherpunk common stock, par value $0.001 per share, CUSIP 52187K200.

Gilead now reports beneficial ownership of 0 shares of Cypherpunk common stock, representing 0% of the class, with no sole or shared voting or dispositive power. The filing states that Gilead's ownership is now "5 percent or less" of the class.

Gilead certifies that any securities referenced were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Cypherpunk, nor in connection with any transaction intended to have that effect.

Cypherpunk Technologies Inc. (CYPH) is the subject of an amended Schedule 13G filing by Gilead Sciences, Inc. covering its holdings of Cypherpunk common stock, par value $0.001 per share, CUSIP 52187K200.

Gilead now reports beneficial ownership of 0 shares of Cypherpunk common stock, representing 0% of the class, with no sole or shared voting or dispositive power. The filing states that Gilead's ownership is now "5 percent or less" of the class.

Gilead certifies that any securities referenced were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Cypherpunk, nor in connection with any transaction intended to have that effect.